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Implication for health policy/practice/research/medical education:
In a study on 68 hemodialysis participants, no significant differences of Anti-HBs antibody between diabetic and non-diabetics or male 
and female subjects were observed. There were not significant correlation between anti-HBs antibody and age, proportion of hemodialysis, 
duration of hemodialysis or hemodialysis efficacy. In this study, there was not significant correlation between serum antibody level against 
hepatitis B surface antigen and some demographic indices of hemodialysis patients, however, these findings need to re-test in other centers 
with more participants. 
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To evaluate the immune response to hepatitis B vaccination in stable hemodialysis (HD) patients, a 
retro-prospective investigation was conducted on 68 HD patients. Participants were vaccinated against 
hepatitis B virus with an intramuscular hepatitis B vaccination schedule, 40 micrograms at 0, 1, and 6 
months. The serum antibody level against hepatitis B surface antigen (HBs) in HD patients was 35±55. In 
this study, no significant differences of Anti-HBs antibody between diabetic and non-diabetics or male 
and female subjects were observed. There were not any significant correlation between antibody against 
HBs-Ag and serum albumin. There was not significant correlation between anti-HBs antibody and age, 
proportion of HD, duration of HD or dialysis efficacy. In this study, there was not significant correlation 
between serum antibody level against hepatitis B surface antigen and some demographic indices of HD 
patients, however, these findings need to re-test in other centers with more participants. 
Introduction 
One of the reasons for increased mortality and morbidity in 
hemodialysis patients is due to high vulnerability to various 
infections like hepatitis B virus (HBV) (1). Vaccination against 
HBV vaccination is routinely done for all patients undergoing 
hemodialysis (HD) (1,2). Nevertheless, antibody production is 
much lower than in healthy persons (2,3). It has been observed 
that around 30–40% of HD patients fail to make antibody 
against HBV after vaccination (3,4). Also HD patients also 
have an incapability to keep appropriate antibody level during 
time (5). In this study, we aimed to examine some demographic 
indices which might influence the antibody production during 
HBV vaccination in a group of stable HD patients. 
Patients and Method 
Patients 
This cross-sectional study was conducted on a group of 
HD patients under regular hemodialysis. Exclusion criteria 
included: using any antibiotics or NSAIDs, or existence of 
infection.
Hepatitis B Vaccination 
The vaccination of HD patients was started before the study 
through a schedule of 0, 1, and 6 months. They received 2 
ml (40μg) of Euvax Hbs-Ag, through intramuscular deltoid 
injections. 
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Laboratory Methods 
Blood samples were collected for assessment of antibody to 
hepatitis B surface antigen (anti-HBs) by ELISA technique with 
Dialab kits (manufactured in Austria) at least 6 months after 
completion of initial vaccination series to assess response to 
vaccination. A participant had responded to the vaccine if the 
anti-HBS level was>10 mIU/ml. Subjects with levels 10–100 
mIU/ml were assumed to be ‘poor responders’, while persons 
with levels>100 mIU/ml were considered as ‘good responders’ 
(1). To assess the efficacy of HD, urea reduction rate (URR) was 
calculated from pre- and post-blood urea nitrogen (BUN) data 
(6). Duration and proportion of HD sessions were determined 
from the patients’ records. The length of each HD session was 
4 hours. 
Ethical issues
The research followed the tenets of the declaration of Helsinki; 
written informed consent was obtained and the research was 
approved by ethical committee of Shahrekord University of 
Medical Sciences.
Statistical analysis 
Data were determined as the mean±standard deviation (SD), 
median and range values. Comparison between the groups 
was performed using Student’s t-test. Statistical correlations 
were evaluated using partial correlation test. All statistical 
analyses were performed using SPSS (version 11.5). Statistical 
significance was determined at p< 0.05.
Results
Total patients were 68 (female=19, male=49). The mean age 
of the patients was 53±18 years. The mean duration of HD 
was 27±29 months (Median: 22.8 months). The mean anti-
HBS-Ab titer was 35±55 (median=5.5). There was not any 
significant difference of antibody production against HBS-Ag 
between male and female or diabetic and non-diabetic subjects 
(p= N.S). There was not significant association of serum 
albumin with antibody against anti-HBS-Ab. Also, there was 
not any significant association of anti-HBS-Ab titer with age, 
proportion of HD, duration of HD or URR, (p= N.S.). 
Discussion 
In this study, there were not any significant differences of 
antibody production against hepatitis B surface antigen between 
diabetic and non-diabetics or male and female subjects. There 
was not significant association between anti-HBs antibody titer 
and age, proportion of hemodialysis, duration of hemodialysis 
or dialysis efficacy. While vaccination can offer significant 
protection against hepatitis B virus infection, vaccine response 
rates are low and unpredictable between dialysis patients (2–
5). It was observed that 34–88% of vaccinated HD patients 
produced protective levels of anti-HB antibody, and few data 
exist assessing the persistence of this response (2,5). Because of 
the impaired immune response, HD patients are given larger 
doses of the vaccine and frequently require revaccination or 
booster doses to produce and maintain adequate anti-HB titers 
(7,8). Given the limited efficacy of hepatitis B vaccine in HD 
patients, it would be useful to define factors that may affect 
vaccine response in HD patients. In fact, unresponsiveness to 
HBV vaccine is multifactorial, and linked to the presence of 
several interacting factors. Various findings have shown that 
response rates are greatest among HD patients younger than 
40 years (5) and sex may also influence vaccine response (8). 
However, other studies, the same as our findings have failed 
to show that sex or proportion of HD influence response to 
hepatitis B vaccine (3–5). Ibrahim et al. studied the evolution 
of anti-HBS Ag antibody after primary vaccination in 29 
HD patients and showed no significant correlation with age 
and duration of HD therapy. They found that responders to 
primary vaccination had significantly higher levels of URR. 
They also found the response to hepatitis B vaccination in 
HD patients neither correlated with nutritional status nor 
age or systemic inflammation. However, adequate HD was 
correlated with good response to hepatitis B vaccine (9). Kara 
et al. in a retrospective study on 34 HD patients found that 
the immune response of the HBV vaccine was low in these 
patients and it was affected by some factors such as nutritional 
status (10). Kovacic et al. conducted a study to find out how 
dialysis adequacy affects response to HBV vaccination. They 
found that the group of good responders had a significantly 
better HD adequacy than the group of non-responders. Kt/V 
values showed a significantly positive correlation with the 
HBs-Ab level. They concluded that efficient HD significantly 
improved the response to vaccination against hepatitis B (11). 
Likewise Ocak et al. aimed to investigate whether HD patients 
suffering from diabetes mellitus could be considered at risk 
for the development of the protective antibodies to hepatitis B 
vaccination. They conducted a study on forty-nine HD patients 
and showed that diabetic patients on HD might carry a greater 
risk of not seroconverting than non-diabetic ones for antibody 
response to HB vaccination (12). Sorkhi et al. in a study on 
62 HD patients showed duration of HD had no influence on 
response to vaccination (13). 
Conclusion 
In this study, we concluded that factors associated with serum 
antibody level against hepatitis B surface antigen were different 
in our HD patients and various factors might be responsible for 
antibody production and more multicenter investigations need 
to define these related factors. 
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